Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30848471 | 1.00 | DYRK1A (0.35) | DYRK1AMAPTLMNAHTTBLM | |
| SCHEMBL126525 | 0.75 | DYRK1A (0.46) | DYRK1AMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15435737 | 0.75 | DYRK1A (0.39) | DYRK1AMAPTHTTRAB9ANPC1 | |
| SCHEMBL21935993 | 0.75 | DYRK1A (0.35) | DYRK1AMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29618341 | 0.75 | DYRK1A (0.46) | DYRK1AMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL25768673 | 0.75 | DYRK1A (0.35) | DYRK1AMAPTRAB9ASMN1; SMN2PKM | |
| SCHEMBL12526763 | 0.75 | DYRK1A (0.33) | DYRK1A | |
| SCHEMBL23376851 | 0.73 | MAOB (0.38) | DYRK1AMAPTLMNAHTTBLM | |
| SCHEMBL2303700 | 0.73 | MAPT (0.33) | DYRK1AMAPTLMNAHTTBLM | |
| SCHEMBL14358232 | 0.72 | MAPT (0.39) | MAPTLMNAHTTBLMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566612-A2 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Recurium IP Holdings, LLC (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3762385-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS LLC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240391924-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2024-11-28 | — | — | US | disclosed |
| US-11261192-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones | RECURIUM IP HOLDINGS, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2022-01-27 | — | — | US | disclosed |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2021-05-13 | — | — | US | disclosed |
| EP-3762385-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Recurium IP Holdings, LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| WO-2019173082-A1 | SUBSTITUTED L,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Zeno Royalties & Milestones, LLC (US) | 2019-09-12 | — | — | WO | disclosed |
| US-9530969-B2 | Material for organic electroluminescence device and organic electroluminescence device | IDEMITSU KOSAN CO., LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261192-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones | MKI67, BRCA1, CCNI | DYRK1A 2828/4885MAPT 2838/4885LMNA 4209/4885 |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | DYRK1A 2828/4885MAPT 2838/4885LMNA 4209/4885 |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | DYRK1A 2828/4885MAPT 2838/4885LMNA 4209/4885 |
| US-20240391924-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | DYRK1A 2828/4885MAPT 2838/4885LMNA 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.